IL16 and Alzheimer disease: These methods have also been used to identify treatment response markers, measuring levels of chemokines and cytokines such as IL-22 and IL-16 before and after treatment with topical corticosteroids, showing a decrease in observed levels, and even correlating the decrease in IL-16 with clinical improvement after topical treatment.37, 38 In 2023, Bakker et al. conducted a review of various studies that attempted to classify AD patients based on their immunologic biomarkers.39